Unlocking Opportunities in the Pharmaceutical Continuous Manufacturing Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Pharmaceutical Continuous Manufacturing Industry Market Size Be by 2025?
The market size for pharmaceutical continuous manufacturing has experienced a noticeable expansion in the last few years. It is projected to increase from $2.47 billion in 2024 to $2.72 billion in 2025, rising at a CAGR of 10.2%. The historical growth has been driven by factors including enhancements in quality and efficiency, shorter time-to-market duration, lower costs and increase in operational efficiency, backing from regulatory authorities, and flexibility and scalability.

What's the Long-Term Growth Forecast for the Pharmaceutical Continuous Manufacturing Market Size Through 2029?
The market for continuous manufacturing in the pharmaceutical industry is projected to experience a swift expansion in the coming years. The market is expected to surge to a value of $4.15 billion by 2029, with a compound annual growth rate (CAGR) of 11.2%. The growth anticipated during the forecast period is attributed to the escalation in the manufacturing of generic drugs, biopharmaceuticals, and personalized medicines, as well as an emphasis on patient-oriented approaches. Key trends expected during this time span include the implementation of continuous manufacturing, the integration of process analytical technology, the application of state-of-the-art automation and robotics, strategic collaborations and partnerships and advances in digitalization and connectivity.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pharmaceutical-continuous-manufacturing-global-market-report

What Are the Key Growth Drivers Fueling the Pharmaceutical Continuous Manufacturing Market Expansion?
An increase in various long-lasting health conditions is anticipated to spur the expansion of the pharmaceutical continuous manufacturing market. These chronic ailments, which usually persist for more than a year, require ongoing medical care and disrupt routine activities. Pharmaceutical companies can optimize drug manufacturing through continuous manufacturing methods, increasing efficiency and reducing expenses. It also improves the reach of necessary drugs, particularly crucial for managing chronic diseases necessitating prolonged medication administration. An April 2022 report by the National Association of Chronic Disease Directors (NACDD), an American non-profit Public Health organization dedicated to managing chronic disease programs, recorded that roughly 60% of adult Americans suffer from a single chronic illness, while around 40% have multiple chronic conditions (MCC). Predictions suggest these health conditions could cost the American economy annually $2 trillion, equivalent to $8,600 per individual by 2030. Hence, the escalating incidence of multiple chronic illnesses is likely to fuel the pharmaceutical continuous manufacturing market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12123&type=smp

What Are the Key Trends Driving Pharmaceutical Continuous Manufacturing Market Growth?
The rise of technological advancements is a significant trend within the pharmaceutical continuous manufacturing market. In their quest to maintain their position, prominent companies within this market are developing new products. In a notable example from December 2022, The United States Pharmacopeia (USP), a not-for-profit organization with rights to the Pharmacopeia National Formulary (USP-NF), launched the USP Advanced Manufacturing Technology Lab. This unveiling was accompanied by the debut of R&D analytical solutions which are purposed to assist drug manufacturers in integrating more advanced manufacturing technologies, including pharmaceutical continuous manufacturing (PCM). The initiative aims to promote geographical variety in the pharmaceutical industry and bolster the resilience of the medicine supply chain. Additionally, it involves the description of materials and the development of methods that guarantee the quality of PCM-based drugs.

How Is the Pharmaceutical Continuous Manufacturing Market Segmented?
The pharmaceutical continuous manufacturing market covered in this report is segmented -

1) By Product: Integrated Continuous System, Control And Software, Semi-Continuous System
2) By Therapeutics Type: Large Molecule, Small Molecule
3) By Formulation: Solid Formation, Liquid And Semi-Solid Formation
4) By Application: Final Drug Product Manufacturing, Active Pharmaceutical Ingredient (API) Manufacturing
5) By End-Users: Pharmaceutical Companies, Contract Manufacturing Organization, Other End-Users

Subsegments:
1) By Integrated Continuous System: Continuous Mixer Systems, Continuous Granulation Systems, Continuous Tablet Press Systems, Continuous Coating Systems
2) By Control and Software: Process Analytical Technology (PAT) Tools, Manufacturing Execution Systems (MES), Control Software for Automation, Data Management and Visualization Software
3) By Semi-Continuous System: Batch-to-Continuous Transition Systems, Hybrid Systems, Semi-Continuous Granulation and Drying Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12123&type=smp

Which Companies Are Leading the Charge in Pharmaceutical Continuous Manufacturing Market Innovation?
Major companies operating in the pharmaceutical continuous manufacturing market include Pfizer Inc., Robert Bosch GmbH, Siemens AG, Novartis AG, Thermo Fisher Scientific Inc., GlaxoSmithKline Plc., Eli Lilly and Company, Corning Inc., Vertex Pharmaceuticals, Lonza Group Ltd., GEA Group AG, Catalent Inc., Mettler Toledo, Patheon, Cytiva, Samsung Biologics Co.Ltd., WuXi Biologics, Syntegon Technology GmbH, Coperion GmbH, Hosokawa Micron Group, FUJIFILM Diosynth Biotechnologies, Leistritz AG, Glatt GmbH, Freund-Vector Corp., SK biotek Co. Ltd., Gericke AG, GEBRÜDER LÖDIGE MASCHINENBAU GmbH, Munson Machinery Company Inc., L.B. Bohle Maschinen und Verfahren GmbH, KORSCH AG, Chemtrix BV

Which Regions Are Leading the Global Pharmaceutical Continuous Manufacturing Market in Revenue?
Western Europe was the largest region in the pharmaceutical continuous manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical continuous manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12123

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.